Blinatumomab and Pembrolizumab

Tabor, Emily E.; Waddell, J. Aubrey; Solimando, Dominic A.

doi:10.1310/hpj5004-269

Cited by 4 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The infusion should be prepared under aseptic conditions 49,53 . The different steps of preparation are: Reconstitute the blinatumomab vial with 3 mL of water for injection by running the water down the sides of the vial to avoid foaming 49,54 Gently shake the vial to avoid excessive foaming: the resulting solution has a concentration of 12.5 μg/mL with a final volume of 3.08 mL 49,55 …”

Section: Resultsmentioning

confidence: 99%

“…Gently shake the vial to avoid excessive foaming: the resulting solution has a concentration of 12.5 μg/mL with a final volume of 3.08 mL 49,55 Add 5.5 mL of stabilizing solution to a pre‐filled 250 mL bag of 0.9% sodium chloride 49,54,55 …”

Section: Resultsmentioning

confidence: 99%

“…Note: the infusion bags, pump cassettes and tubing used must be made of polyolefin or polyvinyl chloride (PVC) without diethylhexylphthalate (DEHP) or ethyl vinyl acetate (EVA) 49,55,56 Gently mix this bag 49,54,55 . The stabilizing solution prevents blinatumomab from sticking to IV bags and tubing 26 …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials

Mocquot

Mossazadeh

Lapierre

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objective Bispecific drugs (BDs) belong to the family of immunotherapies along with checkpoint inhibitors and CAR‐T cells. In the field of oncology, BDs are designed to simultaneously bind a tumour antigen on the one side and an antigen present on the surface of effector cells on the other. This review summarizes the information available to date on the first marketed BiTE‐format bispecific antibody, blinatumomab BLINCYTO® in acute lymphoblastic leukaemia. Methods A literature search was conducted in the PubMed database by including studies published in English using the term blinatumomab. Furthermore, bibliographies of selected references were also evaluated for relevant articles. Clinical trial (CT) data were retrieved from clinicaltrials.gov (ongoing trials, adverse events [AEs]) and global pharmacovigilance data were retrieved from VigiBase®. Results and discussion Blinatumomab is a fusion protein which consists of two single‐chain variable fragments arranged in tandem: the first binds the CD19 surface antigen of all B cells and the second targets the CD3 antigen of T cells. Binding of blinatumomab to B and T cells induces apoptosis of B cells after secretion of granzymes and perforins by T cells. T‐cell activation results in secretion of pro‐inflammatory cytokines and upregulation of activation markers and adhesion molecules on the surface of T cells. The major CTs that led to an indication show increased overall survival with blinatumomab with better efficacy in patients in haematological remission with minimal residual disease ≥10−3. The major AEs are cytokine release syndrome, neurotoxicity and hypogammaglobulinemia. The three most frequent system organ classes in CTs are haematological, gastrointestinal and general disorders. These results are also found in VigiBase® but neurological disorders and infections appear more frequently in real life. What is new and conclusion This review summarizes the current knowledge of blinatumomab in the literature. The subject of many CTs is to improve the route of administration and expand the indications for treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials

Mocquot

Mossazadeh

Lapierre

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

show abstract

“…Blinatumomab can be used as mono-therapy in pediatric recipients, aged from 1 year and over, with relapsed or refractory B-cell precursor ALL, positive for CD19 receptor and negative for Philadelphia chromosome. 2 , 3 , 4…”

Section: Introductionmentioning

confidence: 99%

“…Blinatumomab bridges the two cells by binding the two receptors (CD3 and CD19) and stimulates the immune system to recognize and eliminate malignant cells. 2 , 3 , 4…”

Section: Introductionmentioning

confidence: 99%

Pediatric blinatumomab preparation: Risk assessment on SmPC for software compliance

Cirino

Provasi

Cebulec

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Blinatumomab is an anticancer drug used in the treatment of Acute Lymphoblastic Leukaemia (ALL) in both adults and children. ALL is the most common form of cancer in children and patients who are refractory to standard treatments have poor prognosis. The preparation of blinatumomab is unique and extremely complex. It’s important to carry out any information to identify all the critical issues related to the preparation of blinatumomab: sharing procedure between prescribers, staff of the Centralized Chemotherapy Preparation Unit [Unità Farmaci Antiblastici (UFA)] and administering nurses aimed at reducing the clinical risk related to the management of the drug blinatumomab and to obtain correct prescriptions on the real dose to be prepared, safe worksheets with computer processing of all variables (volumes to be added and corresponding dose of drug) and complete labels containing all the information necessary for the control of the preparation and its correct infusion. Methods A computerized process involves the use of specific software to which precise instructions must be given. This study is divided into two phases, the first one focused on the analysis of Summary of Product Characteristics (SmPC) and the extrapolation of any unclear part of SmPC. The second phase involved the manufacturer to answer a questionnaire. Results This comparison with the company allowed to perfect the blinatumomab preparation process leading to: 1. allow the patient to be discharged and return a few times for infusions and consequently reduce the number of medical prescriptions; 2. set up the drug for each patient every 4 days; 3. reduce costs related to devices, staff employed. Conclusion Computerizing the preparation of anti-blastic drugs is a necessary path for the safety of the patient and all the operators involved, however it may be necessary to make changes in the preparation process to allow the software to work correctly. The comparison between pharmacist, clinician and, where necessary, the manufacturer of the drug, was effective in the preparation of this drug.

show abstract

Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective

Delea

Amdahl

Boyko

et al. 2017

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Blinatumomab and Pembrolizumab

Cited by 4 publications

References 13 publications

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials

Pediatric blinatumomab preparation: Risk assessment on SmPC for software compliance

Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective

Contact Info

Product

Resources

About